Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis
Sena, Elena (Vall d'Hebron Institut de Recerca (VHIR))
Tacke, Frank (Charité-Universitätsmedizin Berlin)
Anstee, Quentin M. (Newcastle University(Regne Unit))
Di Prospero, Nicholas (Janssen Research and Development (Raritan, Estats Units d'Amèrica))
Skalshøi- Kjær, Mette (Novo Nordisk (Bagsvaerd, Dinamarca))
Muñoz-Martínez, S. (Vall d'Hebron Institut de Recerca (VHIR))
Rivera Esteban, Jesús (Vall d'Hebron Institut de Recerca (VHIR))
Jiménez-Masip, Alba (Vall d'Hebron Institut de Recerca (VHIR))
Bañales, Jesús M. (Universidad del País Vasco)
Martínez-Gómez, María (Vall d'Hebron Institut de Recerca (VHIR))
Koenig, Franz (Medical University of Vienna)
Genescà Ferrer, Joan (Vall d'Hebron Institut de Recerca (VHIR))
Ratziu, Vlad (University Paris 6)
Pericàs, Juan M. (Vall d'Hebron Institut de Recerca (VHIR))

Data:	2024
Resum:	The EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project (IMI2-853966) aimed to develop tools to establish integrated research platforms (IRP) for conducting adaptive-design trials in various diseases, including metabolic-dysfunction associated steatohepatitis (MASH). One essential component of a successful MASH IRP is a robust and reliable Clinical Research Network (CRN). Herein, we outline the required elements and anticipated steps to set-up such a CRN. We identified European clinical research sites that could potentially serve as the foundation for MASH IRP and a CRN. A survey was sent to sites to assess their interest in joining a CRN, their familiarity with platform trials, and their capacity to participate in a future MASH IRP. A total of 141 investigators were invited to participate in the survey, and 40% responded. More than half of the answers (52%) identify MASH with advanced fibrosis (F3-4) as the subpopulation with the greatest unmet need. Regarding the difficulty in identifying candidates for trials, 65% find it is moderately difficult and 30% very difficult. Most respondents (94%) believe that a platform trial could offer substantial benefits to patients. Nearly all researchers express interest in participating in a platform trial (78%), with 22% indicating their interest would be contingent on initial industry funding. While preliminary, our findings on responding sites are encouraging for the potential establishment of a CRN for a MASH IRP. However, funding schemes and sustainability strategies to provide proof-of-platform in MASH seem key in the short-term scenario. Metabolic dysfunction-associated steatohepatitis (MASH) occurs when the liver becomes damaged due to the build up of fat, which is often related to obesity and diabetes. There is a lack of effective drug treatments for MASH, so strategies to strengthen clinical research in this area are needed. Here, we survey key European experts on MASH to assess their interest in joining a network of MASH researchers and their interest in participating in a new type of clinical trial called a platform trial, where multiple drugs can be tested simultaneously. Researchers largely agree that these are promising approaches to boost drug development in the field, although have concerns regarding funding and sustainability strategies. Our findings may inform the creation of a network of MASH researchers capable of running a platform trial, which in turn may speed up research into treatments for MASH. Sena et al. survey European clinical research sites that could potentially serve as the foundation for a MASH integrated research platform and clinical research network. Respondents generally believe that a MASH platform trial could benefit patients and are interested in participating, though securing industry funding is identified as a priority.
Ajuts:	European Commission 853966 European Commission 847989 Instituto de Salud Carlos III PI19/01898
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Non-alcoholic steatohepatitis ; Randomized controlled trials
Publicat a:	Communications Medicine, Vol. 4 (july 2024) , ISSN 2730-664X

DOI: 10.1038/s43856-024-00560-5
PMID: 39014214

8 p, 869.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats